• Latest Posts

A Year to Remember: The Biggest European Biotech News in 2020

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

Themis and Institut Pasteur Join Coronavirus Vaccine Hunt

Themis Raises €40M for First Phase III Trial of a Chikungunya Vaccine 

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Austrian Biotech Raises €19M to Commercialize First Chikungunya Vaccine

Interview 6 May 2019

2019 Will Be a “Year of Realism” for Biotech Investments

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases